Genomic findings in patients with clinical suspicion of 22q11.2 deletion syndrome by Magdalena Koczkowska et al.
HUMAN GENETICS • ORIGINAL PAPER
Genomic findings in patients with clinical suspicion of 22q11.2
deletion syndrome
Magdalena Koczkowska1 & Jolanta Wierzba2 & Robert Śmigiel3 & Maria Sąsiadek4 &
Magdalena Cabała3 & Ryszard Ślężak4 & Mariola Iliszko1 & Iwona Kardaś1 &
Janusz Limon1 & Beata S. Lipska-Ziętkiewicz1
Received: 25 April 2016 /Revised: 15 August 2016 /Accepted: 29 August 2016 /Published online: 14 September 2016
# The Author(s) 2016. This article is published with open access at Springerlink.com
Abstract Chromosome 22q11.2 deletion syndrome, one of
the most common human genomic syndromes, has highly
heterogeneous clinical presentation. Patients usually harbor a
1.5 to 3 Mb hemizygous deletion at chromosome 22q11.2,
resulting in pathognomic TBX1, CRKL and/or MAPK1
haploinsufficiency. However, there are some individuals with
clinical features resembling the syndrome who are eventually
diagnosed with genomic disorders affecting other chromo-
somal regions. The objective of this study was to evaluate
the additive value of high-resolution array-CGH testing in
the cohort of 41 patients with clinical features of 22q11.2
deletion syndrome and negative results of standard cytogenet-
ic diagnostic testing (karyotype and FISH for 22q11.2 locus).
Array-CGH analysis revealed no aberrations at chromosomes
22 or 10 allegedly related to the syndrome. Five (12.2 %)
patients were found to have other genomic imbalances, name-
ly 17q21.31 microdeletion syndrome (MIM#610443), 1p36
deletion syndrome (MIM#607872), NF1 microduplication
syndrome (MIM#613675), chromosome 6pter-p24 deletion
syndrome (MIM#612582) and a novel interstitial deletion at
3q26.31 of 0.65 Mb encompassing a dosage-dependent gene
NAALADL2. Our study demonstrates that the implementation
of array-CGH into the panel of classic diagnostic procedures
adds significantly to their efficacy. It allows for detection of
constitutional genomic imbalances in 12 % of subjects with
negative result of karyotype and FISH targeted for 22q11.2
region. Moreover, if used as first-tier genetic test, the method
would provide immediate diagnosis in ∼40 % phenotypic
22q11.2 deletion subjects.
Keywords 22q11.2 deletion syndrome . Array comparative
genomic hybridization . 17q21.31microdeletion syndrome .
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Introduction
Chromosomal rearrangements of 22q11.2 are implicated in
several genomic disorders, microdeletion 22q11.2 being the
most common recurrent syndrome with a prevalence of
∼1:4000–1:6000 live births (Grati et al. 2015). The phenotype
of patients with the deletion at 22q11.2 chromosome encom-
passes a number of clinical entities, including DiGeorge syn-
drome (DGS; MIM#188400) and velocardiofacial syndrome
(VCFS; MIM#192430). The cardinal features comprise
conotruncal heart defects, characteristic dysmorphic facies
(unusually shaped ears, long nose with broad bridge,
micrognathia and upslanting, short palpebral fissures) and
velophryngeal insufficiency or cleft palate. Individuals with
the more severe phenotype present T-cell immunodeficiency
and persistent hypocalcaemia (Tobias et al. 1999; Bassett et al.
2011). Moreover, the presence of some features is determined
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by the age of individual, for instance psychiatric disorders are
more commonly observed in adults (Schneider et al. 2014).
In 90 % of patients with the 22q11.2 deletion, a common
∼3 Mb deletion has been found, whereas 7 % of cases share a
smaller, nested ∼1.5 Mb recurrent deletion. Among the re-
maining individuals atypical deletions or chromosomal trans-
locations involving 22q11.2 have been reported (Schwinger
et al. 2010). So far, haploinsufficiency of three genes (TBX1,
CRKL and MAPK1) on 22q11.2 has been reported strongly
associated with the syndrome (Schwinger et al. 2010;
Breckpot et al. 2012; Rump et al. 2014; Racedo et al. 2015).
Due to the wide variability in the clinical presentation, the
diagnosis based on phenotype evaluation is challenging. Even
though the state-of-art diagnostic procedure for patients with
the clinical suspicion of the 22q11.2 deletion syndrome is the
targeted FISH testing, at present patients are usually diag-
nosed by indirect whole-genome studies, array-CGH being
the case in point. Indeed, array-CGH has been recommended
as the first-tier diagnostic test for patients with multiple con-
genital anomalies, developmental delay/intellectual disability
and/or autism spectrum disorders; the indications fulfilled also
with respect to 22q11.2 deletion syndrome (Henderson et al.
2014).
The aim of the current study was to estimate the efficacy of
implementation of the array-CGH screening into the panel of
classic diagnostic procedures in subjects resembling the
22q11.2 deletion phenotype. Accordingly, we have applied
array-CGH technique to evaluate the incidence and to charac-
terize genomic disorders in the group of patients with clinical
features of 22q11.2 deletion syndrome and a normal karyo-
type and negative result of FISH for 22q11.2 locus.
Clinical report
Enrollment procedure
Patients from two clinical genetics outpatient clinics (at
Gdansk and Wroclaw Medical Universities) were suspected
of 22q11.2 deletion syndrome in view of the Tobias criteria
(see below) (Tobias et al. 1999). In the years 2004–2014 the
confirmation rate of the syndrome established through FISH
studies performed using the commercially available D22S75/
N25 probe (Cytocell) was 15.8 %. In addition, five patients
(11.8 %) were diagnosed with a chromosomal aberration in
view of matched karyotype studies. The findings included two
cases of a familial translocation (4;11); one case of an unbal-
anced (X;6) translocation, one case of an unbalanced (14;18)
translocation and one case of a large interstitial deletion at
chromosome 6q. The remaining patients with the phenotype
of 22q11.2 deletion syndrome and with normal results of the
standard diagnostic testing (karyotype and targeted FISH)
were contacted retrospectively and after obtaining informed
consent eventually enrolled in the study.
Cohort description
The patients were evaluated by two clinical geneticists in view
of the Tobias criteria (Tobias et al. 1999). Detailed clinical
description of the patients is presented in Supplementary data
1. In brief, 20 (49 %) and 21 (51 %) out of 41 patients met one
of the A criteria and at least two of the B criteria, respectively.
None of the individuals were diagnosed based on the C
criteria. Cardiac defects were detected in 90 % of patients
(n = 37), including a conotruncal anomaly and Fallot’s tetral-
ogy in 51 % (19/37) and 16 % (6/37), respectively.
Characteristic facial features associated with 22q11.2 deletion
syndrome were described in 33 patients (80 %); the most
frequent being micro(retro)gnathia (58 %), unusually shaped
ears (55 %), long nose with broad bridge (52 %) and short
palpebral fissures (30 %). Learning difficulties and/or devel-
opmental delay were reported in 24 individuals (59 %),
whereas 17 % and 5 % of cases were diagnosed with cleft
palate and velopharyngeal insufficiency, respectively.
Moreover, a total of 16 patients (39 %) had swallowing diffi-
culties. Other anomalies, such as short stature and renal ab-
normalities were found in 17 % and 15 % of patients, respec-
tively. Only 5 % (2/38) of patients had primary immunodefi-
ciency while none presented with persistent hypocalcaemia.
Methods
Array-CGH was performed at resolution of 25 kb using
Human CGH 3x720K Whole-Genome Tilling Array (Roche,
Basel, Switzerland) following the instructions provided by
manufacturer with modifications as previously described
(Ronowicz et al. 2012). All identified genomic imbalances
were verified in the general access databases of genomic var-
iants (DGV, ISCA and Decipher; last accessed December
2015). In selected cases, the de novo/familial origin of the
aberration was established using qPCR technique. The study
was approved by the Research Ethics Committee of Medical
University of Gdansk.
Results
No genomic aberrations at chromosomes 10 and 22 purport-
edly related to the syndrome were detected. Five patients
(12.2 %) were found to have a submicroscopic genomic im-
balances of the mean size of 1.5 Mb (Table 1). Patient 29
harbored a 2.1 interstitial deletion of chromosome
1p36.33p36.32, encompassing a total number of 82 genes,
including the GABRD and SKI genes, the region typical for
the 1p36 deletion syndrome (MIM#607872). In the individual
22 array-CGH analysis revealed a 2.7 Mb terminal deletion of
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chromosome 6p25.3p25.2, the minimal region of chromo-
some 6pter-p24 deletion syndrome (MIM#612582), covering
a total number of 18 genes, among which FOXC1 is pro-
posed as the candidate gene correlating with the reported
phenotype. Also, two individuals had interstitial aberrations
at chromosome 17. Patient 15 presented with an 1.5 Mb du-
plication at 17q11.2, whereas a small deletion of 0.5 Mb at
17q21.31 was found in patient 18. The findings correspond
with clinical diagnosis of NF1 microduplication syndrome
(MIM#613675) and Koolen–de Vries syndrome
(MIM#610443) respectively. A comparison of overlapping
and distinct clinical features between the detected genomic
disorders and the phenotype associated with 22q11.2 deletion
is presented in Table 1.
Finally, a unique loss at chromosome 3q26.31 of 650 kb
encompassing the entire NAALADL2 gene sequence, was
identified in patient 41. qPCR analysis revealed the same
deletion in two siblings of the patient (a sister with bilateral
cleft lip and palate and a brother with congenital heart defect)
and their apparently unaffected mother (for details see
Supplementary data 2).
Discussion
Nowadays, the gold standard diagnostic procedure for
22q11.2 deletion syndrome is by conventional cytogenetic
technique and targeted FISH analysis (Schwinger et al.
2010). Several studies have demonstrated that according to
this approach the detection rate varies considerably (4–96 %)
(Yagi et al. 2003; Smigiel et al. 2007; Brunet et al. 2009;
Fernandez et al. 2008; Wozniak et al. 2010). However, a
more practical approach is to perform a whole-genome anal-
ysis, as it not only allows one to identify the syndrome but at
the same time may detect any other genomic syndrome pre-
senting overlapping clinical features. To the best of our
knowledge, our work is the first attempt to evaluate applica-
tion of aCGH technique in the cohort of patients presenting
phenotype resembling the 22q11.2 deletion syndrome.
To date, over 180 clinical features have been associated
with the 22q11.2 deletion syndrome. Clinical diagnosis of
22q11.2 deletion syndrome remains a challenging task, be-
cause no single pathognomonic finding exists for the syn-
drome. Even though it has been postulated that the two major
striking phenotypic features are: immunodeficiency and
hypocalcaemia (Bassett et al. 2011), that was not shown in
the large series of patients. Similar to the current series, in the
recent report of almost 750 cases diagnosed in France over
last 18 years the most frequent reasons for referral of postna-
tally diagnosed cases were a congenital heart defect (49 %),
facial dysmorphism (50 %) and developmental delay (41 %).
Hypocalceamia was present in 15 % only, while immunode-
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infections were reported in 8 % and thymus agenesis in 7 %.
Actually, 25 % of the patients were referred because of a
single feature; of these, half had a congenital heart defect only
(Poirsier et al. 2015).
In the last ten years, the clinical diagnosis of the syndrome
has been confirmed by FISH in 16% of the patients referred to
our Outpatient Genetic Clinics (Fig. 1). Concurrent conven-
tional cytogenetic analysis allowed us to identify genomic
imbalances as the underlying cause of the observed phenotype
in additional 12 % of cases.
In this study, 41 patients with clinical signs of 22q11.2 de-
letion syndrome and with negative standard diagnostic analysis
were further evaluated using array-CGH. Five individuals
(12.2 %) were diagnosed to harbor pathogenic genomic imbal-
ances, including four known recurrent genomic disorders
(Table 1). Our findings add on to the clinical spectrum of these
syndromes and show that their clinical manifestation might
mimic the presentation of the 22q11.2 deletion syndrome.
Nonetheless, these patients lacked cardinal clinical signs, such
as conotruncal heart defects or family history of 22q11.2 dele-
tion syndrome; also their dysmorphic features were distinct
from the 22q11.2 deletion phenotype in three of four individ-
uals. Based on the results of array analysis reverse phenotyping
was performed revealing incomplete phenotype in all of them
(Table 1). The patient (#22) with a 2.7 Mb deletion at chromo-
some 6p25 did not present anterior eye chamber abnormalities
(including Axenfeld-Rieger syndrome type 3 in particular) that
are considered pathognomonic for the syndrome. Also, the boy
(#15) with a 1.5 duplication at 17q11.2 encompassing NF1
gene did not present developmental delay or seizures allegedly
reported in patients with such duplication. The girl (#18) with a
0.5 Mb deletion at 17q21.31 presented mild dysmorphic fea-
tures and lacked blepharophimosis, ptosis, or abnormal hair
pigmentation and texture usually observed in children with
Koolen-de Vries syndrome. The girl (#29) with a 2.1 Mb dele-
tion at chromosome 1p36 did not have structural abnormalities
of the brain, vision or hearing impairment or other
malformations usually present in children with the syndrome.
In addition to known recurrent syndromes, we identified a
unique deletion at 3q26.31 of 0.65 Mb size. The deletion
encompasses only one dosage-dependent gene, NAALADL2
(MIM*608806), that is thought to be associated with the con-
genital defects, dysmorphic features and/or development de-
lay (Millson et al. 2012). Family study (Supplementary data 2)
revealed the variant to be present in two affected siblings of
the patient and an apparently healthy mother indicating re-
duced penetrance and variable expressivity.
In the current study no submicroscopic chromosomal rear-
rangements at chromosome 22 or 10 allegedly related to the
syndromewere identified. The losses at DGS2 locus located at
10p13p14 chromosome have an estimated frequency of one in
200,000 live births (Daw et al. 1996; Lindstrand et al. 2010).
The DGS2 clinical presentation is thought to be more severe
than the regular 22q11.2 deletion syndrome with severe men-
tal retardation in addition to immune deficiency and heart
defects. Due to its rarity, and in line with the fact, that only a
small fraction of the subjects studied in the current work pre-
sented with such a severe phenotype, our study might have
disregarded such cases. Otherwise, our results are in line with
the study of Bartsch et al. (1999), suggesting no evidence for
genomic deletions at putative DGS2 locus on 10p in pheno-
typic 22q11.2 deletion patients.
The recommended optimal resolution for array-CGH used
in routine diagnostics, that does not increase greatly the num-
ber of uncertain significance variants, is 200 kb (Vermeesch
et al. 2012). In the current study we have used high-resolution
array-CGH at 25 kb which did not improve diagnostic yield. It
only increased the background noise related to the detected
small CNVs of unknown significance (on average 2 per sam-
ple), eventually proven to be insignificant to the reported phe-
notype. Plausibly, the high resolution could be useful in de-
tecting small aberrations, affecting the locus of TBX1 gene in
particular as previously reported by Chen et al. (2014), but no
atypical small aberration at 22q11.2 locuswas observed in the
current series of patients.
Taking into account the high variability of phenotype in
patients with the clinical suspicion of 22q11.2 deletion syn-
drome, we recommended to use array-CGH as the first-line
genetic test, in place of conventional cytogenetic procedures
and targeted FISH. Array-CGH has proven to increase the
resolution and provide higher diagnostic yield than classical
karyotyping which improves diagnostic capability (Miller
et al. 2010; Kaminsky et al. 2013). In the presented study, if
Fig. 1 The flow-chart showing subsequent detection rates of genomic
disorders in patients with the clinical features of 22q11.2 deletion
syndrome using various testing approaches (targeted FISH followed by
conventional karyotyping, followed by array-CGH)
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array-CGH had been used as the first-tier clinical diagnostic
test it could have confirmed the diagnosis of a genomic disor-
der in ∼40 % of individuals with clinical manifestation of the
22q11.2 deletion syndrome (Fig. 1). The resolution of the
technique without any doubt could detect the imbalances pres-
ent in the patients diagnosed at previous stages of diagnostic
procedures (i.e. by FISH or conventional karyotyping). Array-
CGH appears not only as less time-consuming but also as the
cost-effective technique. In the remaining 60% of patients, the
screening for detection of unknown gene mutations by whole-
exome sequencing (WES) should be considered. In line with
the recommendations of the American College of Medical
Genetics and Genomics (2012) and the European Society of
Human Genetics (2013) WES analysis should be considered
in the clinical evaluation of individuals with suspected genetic
disorders only under certain circumstances. Interpretation of
an enormous amount of raw data and the risk of identification
of incidental (secondary) findings are the main limiting factors
(ACMG 2012; van El et al. 2013).
In conclusion, our study confirms that array-CGH screen-
ing of individuals with clinical suspicion of 22q11.2 and the
negative result of standard genetic testing increases the capac-
ity to detect submicroscopic chromosomal aberrations and
therefore allows one to make the proper diagnosis in a signif-
icant fraction of patients. Accordingly, we recommend array-
CGH testing as the first choice test in this particular clinical
setting.
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